Published in Bull World Health Organ on January 01, 2002
Eradicating poliomyelitis: India's journey from hyperendemic to polio-free status. Indian J Med Res (2013) 1.50
Estimating the extent of vaccine-derived poliovirus infection. PLoS One (2008) 1.05
Vaccine-associated paralytic polio in India. Bull World Health Organ (2002) 0.93
Molecular epidemiology and recombination of human enteroviruses from AFP surveillance in Yunnan, China from 2006 to 2010. Sci Rep (2014) 0.84
A mucosal adjuvant for the inactivated poliovirus vaccine. Vaccine (2013) 0.80
Further clarity on vaccine-associated paralytic polio in India. Bull World Health Organ (2003) 0.77
Immunogenicity and safety of 3-dose primary vaccination with combined DTPa-HBV-IPV/Hib in Indian infants. Hum Vaccin Immunother (2016) 0.75
Vaccine-associated paralytic poliomyelitis: a case report of flaccid monoparesis after oral polio vaccine. J Korean Med Sci (2007) 0.75
Polio Eradication in India: Myth or Reality. Med J Armed Forces India (2011) 0.75
Vaccine-derived polioviruses and the endgame strategy for global polio eradication. Annu Rev Microbiol (2005) 4.42
Protective efficacy of a monovalent oral type 1 poliovirus vaccine: a case-control study. Lancet (2007) 3.73
New strategies for the elimination of polio from India. Science (2006) 3.27
Reasons related to non-vaccination and under-vaccination of children in low and middle income countries: findings from a systematic review of the published literature, 1999-2009. Vaccine (2011) 2.70
Vaccine policy changes and epidemiology of poliomyelitis in the United States. JAMA (2004) 2.60
A global call for new polio vaccines. Nature (2005) 2.26
Fractional doses of inactivated poliovirus vaccine in Oman. N Engl J Med (2010) 2.21
Immunogenicity of supplemental doses of poliovirus vaccine for children aged 6-9 months in Moradabad, India: a community-based, randomised controlled trial. Lancet Infect Dis (2011) 2.06
Mucosal immunity after vaccination with monovalent and trivalent oral poliovirus vaccine in India. J Infect Dis (2009) 2.05
Why children are not vaccinated: a review of the grey literature. Int Health (2012) 1.91
Elimination of cholera transmission in Haiti and the Dominican Republic. Lancet (2012) 1.91
Expansion of seasonal influenza vaccination in the Americas. BMC Public Health (2009) 1.83
Persistence of vaccine-derived polioviruses among immunodeficient persons with vaccine-associated paralytic poliomyelitis. J Infect Dis (2003) 1.79
Monovalent type 1 oral poliovirus vaccine in newborns. N Engl J Med (2008) 1.49
Economic analysis of the global polio eradication initiative. Vaccine (2010) 1.47
Outbreak of poliomyelitis due to type 3 poliovirus, northern India, 1999-2000: injections a major contributing factor. Int J Epidemiol (2003) 1.44
Asymptomatic wild-type poliovirus infection in India among children with previous oral poliovirus vaccination. J Infect Dis (2010) 1.28
A dynamic model of poliomyelitis outbreaks: learning from the past to help inform the future. Am J Epidemiol (2005) 1.25
2-[(E)-Meth-oxy-imino]-2-{2-[(2-methyl-phen-oxy)meth-yl]phen-yl}ethanoic acid. Acta Crystallogr Sect E Struct Rep Online (2012) 1.23
Policy. OPV cessation--the final step to a "polio-free" world. Science (2005) 1.19
Randomized controlled clinical trial of fractional doses of inactivated poliovirus vaccine administered intradermally by needle-free device in Cuba. J Infect Dis (2010) 1.19
Expert review on poliovirus immunity and transmission. Risk Anal (2012) 1.18
Randomized trial of type 1 and type 3 oral monovalent poliovirus vaccines in newborns in Africa. J Infect Dis (2011) 1.17
Review and assessment of poliovirus immunity and transmission: synthesis of knowledge gaps and identification of research needs. Risk Anal (2013) 1.16
Waning intestinal immunity after vaccination with oral poliovirus vaccines in India. J Infect Dis (2012) 1.14
Confirmation of rubella within 4 days of rash onset: comparison of rubella virus RNA detection in oral fluid with immunoglobulin M detection in serum or oral fluid. J Clin Microbiol (2008) 1.12
Risks of paralytic disease due to wild or vaccine-derived poliovirus after eradication. Risk Anal (2006) 1.10
Survey of poliovirus antibodies during the final stage of polio eradication in Egypt. Vaccine (2007) 1.07
Update on Vaccine-Derived Polioviruses - Worldwide, January 2014-March 2015. MMWR Morb Mortal Wkly Rep (2015) 1.07
Estimating the extent of vaccine-derived poliovirus infection. PLoS One (2008) 1.05
Strengthening the technical capacity at country-level to make informed policy decisions on new vaccine introduction: lessons learned by PAHO's ProVac Initiative. Vaccine (2010) 1.02
Progress in vaccination against Haemophilus influenzae type b in the Americas. PLoS Med (2008) 1.02
Progress in vaccination against hepatitis B in the Americas. J Clin Virol (2005) 0.99
Compatible poliomyelitis cases in India during 2000. Bull World Health Organ (2003) 0.99
Priming after a fractional dose of inactivated poliovirus vaccine. N Engl J Med (2013) 0.98
Risk management in a polio-free world. Risk Anal (2006) 0.95
Vaccination coverage of foreign-born children 19 to 35 months of age: findings from the National Immunization Survey, 1999-2000. Pediatrics (2002) 0.95
2-(Meth-oxy-imino)-2-{2-[(2-methyl-phenoxy)meth-yl]phen-yl}acetohydrazide. Acta Crystallogr Sect E Struct Rep Online (2012) 0.94
The risks, costs, and benefits of possible future global policies for managing polioviruses. Am J Public Health (2008) 0.94
Shedding of vaccine viruses with increased antigenic and genetic divergence after vaccination of newborns with monovalent type 1 oral poliovirus vaccine. J Virol (2009) 0.92
IAP recommendations on Polio Eradication and Improvement of Routine Immunization. Indian Pediatr (2008) 0.92
Multiresidue pesticide analysis of agricultural commodities using acetonitrile salt-out extraction, dispersive solid-phase sample clean-up, and high-performance liquid chromatography-tandem mass spectrometry. J Agric Food Chem (2011) 0.91
Potential intussusception risk versus health benefits from rotavirus vaccination in Latin America. Clin Infect Dis (2012) 0.90
Poliovirus vaccination options for achieving eradication and securing the endgame. Curr Opin Virol (2013) 0.90
Intestinal immunity is a determinant of clearance of poliovirus after oral vaccination. J Infect Dis (2014) 0.90
A vision of a world without polio: the OPV cessation strategy. Biologicals (2006) 0.89
Prevalence of prolonged and chronic poliovirus excretion among persons with primary immune deficiency disorders in Sri Lanka. Vaccine (2012) 0.89
Systematic documentation of new vaccine introduction in selected countries of the Latin American Region. Vaccine (2013) 0.88
Degradation kinetics and safety evaluation of buprofezin residues in grape (Vitis vinifera L.) and three different soils of India. Pest Manag Sci (2009) 0.87
Mucosal immunity and poliovirus vaccines: impact on wild poliovirus infection and transmission. Vaccine (2011) 0.87
Critical issues in implementing a national integrated all-vaccine preventable disease surveillance system. Vaccine (2013) 0.87
Safety and immunogenicity of inactivated poliovirus vaccine based on Sabin strains with and without aluminum hydroxide: a phase I trial in healthy adults. Vaccine (2013) 0.86
Dissipation and distribution behavior of azoxystrobin, carbendazim, and difenoconazole in pomegranate fruits. J Agric Food Chem (2011) 0.86
Burden of diarrhea among children in Honduras, 2000-2004: estimates of the role of rotavirus. Rev Panam Salud Publica (2006) 0.85
Descriptive analysis of immunization policy decision making in the Americas. Rev Panam Salud Publica (2009) 0.84
Targeting the mitochondrial pathway to induce apoptosis/necrosis through ROS by a newly developed Schiff's base to overcome MDR in cancer. Biochimie (2011) 0.83
Polio control after certification: major issues outstanding. Bull World Health Organ (2004) 0.83
Uncertainty and sensitivity analyses of a decision analytic model for posteradication polio risk management. Risk Anal (2008) 0.83
TRIVAC decision-support model for evaluating the cost-effectiveness of Haemophilus influenzae type b, pneumococcal and rotavirus vaccination. Vaccine (2013) 0.82
Detection of diphtheritic polyneuropathy by acute flaccid paralysis surveillance, India. Emerg Infect Dis (2013) 0.82
Guillain-Barré Syndrome in India: population-based validation of the Brighton criteria. Vaccine (2011) 0.82
Dissipation kinetics of forchlorfenuron, 6-benzyl aminopurine, gibberellic acid and ethephon residues in table grapes (Vitis vinifera). Food Chem (2013) 0.81
Outbreak of rotavirus gastroenteritis with high mortality, Nicaragua, 2005. Rev Panam Salud Publica (2008) 0.81
Multiresidue pesticide analysis in fresh produce by capillary gas chromatography-mass spectrometry/selective ion monitoring (GC-MS/SIM) and -tandem mass spectrometry (GC-MS/MS). J Agric Food Chem (2010) 0.81
Development and consideration of global policies for managing the future risks of poliovirus outbreaks: insights and lessons learned through modeling. Risk Anal (2006) 0.81
Development and interlaboratory validation of a QuEChERS-based liquid chromatography-tandem mass spectrometry method for multiresidue pesticide analysis. J Agric Food Chem (2010) 0.81
Biodegradation of profenofos by Bacillus subtilis isolated from grapevines (Vitis vinifera). J Agric Food Chem (2013) 0.81
Percutaneous fixation of displaced intra-articular calcaneal fracture. J Indian Med Assoc (2011) 0.80
Update on Vaccine-Derived Polioviruses - Worldwide, January 2015-May 2016. MMWR Morb Mortal Wkly Rep (2016) 0.80
Mucosal immunity to poliovirus. Expert Rev Vaccines (2011) 0.80
The molecular interaction of a copper chelate with human P-glycoprotein. Mol Cell Biochem (2012) 0.80
Development of a cholera vaccination policy on the Island of Hispaniola, 2010-2013. Am J Trop Med Hyg (2013) 0.80
Multiresidue pesticide analysis of ginseng powders using acetonitrile- or acetone-based extraction, solid-phase extraction cleanup, and gas chromatography-mass spectrometry/selective ion monitoring (GC-MS/SIM) or -tandem mass spectrometry (GC-MS/MS). J Agric Food Chem (2010) 0.80
Bioefficacy, dissipation kinetics and safety evaluation of selected insecticides in Allium cepa L. J Environ Sci Health B (2012) 0.79
Overcoming multidrug resistance (MDR) in cancer in vitro and in vivo by a quinoline derivative. Biomed Pharmacother (2011) 0.79
Vaccination legislation in Latin America and the Caribbean. J Public Health Policy (2013) 0.79
Immunogenicity of measles and rubella vaccines in Oman: a prospective clinical trial. J Infect Dis (2003) 0.78
Oral and inactivated poliovirus vaccines in the newborn: a review. Vaccine (2012) 0.78
Optimization of two-dimensional gas chromatography time-of-flight mass spectrometry for separation and estimation of the residues of 160 pesticides and 25 persistent organic pollutants in grape and wine. J Chromatogr A (2010) 0.77
Extraction of pesticides, dioxin-like PCBs and PAHs in water based commodities using liquid-liquid microextraction and analysis by gas chromatography-mass spectrometry. J Chromatogr A (2011) 0.77
Degradation of chlorimuron-ethyl by Aspergillus niger isolated from agricultural soil. FEMS Microbiol Lett (2012) 0.77
Iron N-(2-hydroxy acetophenone) glycinate (FeNG), a non-toxic glutathione depletor circumvents doxorubicin resistance in Ehrlich ascites carcinoma cells in vivo. Biometals (2011) 0.77
The role of a Schiff base scaffold, N-(2-hydroxy acetophenone) glycinate-in overcoming multidrug resistance in cancer. Eur J Pharm Sci (2013) 0.77
Further clarity on vaccine-associated paralytic polio in India. Bull World Health Organ (2003) 0.77
An in vitro and in vivo study of a novel zinc complex, zinc N-(2-hydroxyacetophenone)glycinate to overcome multidrug resistance in cancer. Dalton Trans (2011) 0.77
A copper chelate selectively triggers apoptosis in myeloid-derived suppressor cells in a drug-resistant tumor model and enhances antitumor immune response. Immunopharmacol Immunotoxicol (2014) 0.76
Redox active copper chelate overcomes multidrug resistance in T-lymphoblastic leukemia cell by triggering apoptosis. Mol Biosyst (2011) 0.75
1-[(6-Chloro-pyridin-3-yl)meth-yl]-imidazolidin-2-one. Acta Crystallogr Sect E Struct Rep Online (2012) 0.75
Cholera elimination in Hispaniola. Am J Trop Med Hyg (2013) 0.75
Poly[μ₂-aqua-μ₄-(2-{3-[(6-chloro-pyridin-3-yl)meth-yl]-2-oxoimidazolidin-1-yl}acetato)-sodium]. Acta Crystallogr Sect E Struct Rep Online (2012) 0.75
2-Meth-oxy-imino-2-{2-[(2-methyl-phen-oxy)meth-yl]phen-yl}ethanol. Acta Crystallogr Sect E Struct Rep Online (2012) 0.75
Evidence base for new vaccine introduction in Latin America and the Caribbean. Vaccine (2013) 0.75
3-[(2-Chloro-1,3-thia-zol-5-yl)meth-yl]-5-methyl-1,3,5-oxadiazinan-4-one. Acta Crystallogr Sect E Struct Rep Online (2012) 0.75
N-[2-({[1-(4-Chloro-phen-yl)-1H-pyrazol-3-yl]-oxy}meth-yl)phen-yl]-N-meth-oxy-hydrazinecarboxamide. Acta Crystallogr Sect E Struct Rep Online (2012) 0.75